Skip to content
Storytelling Co – Lifestyle
Author:
Tempest Therapeutics
Tempest Presents Clinical Update at ISCT 2026 Annual Meeting
May 6, 2026
Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting
April 29, 2026
Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T
April 22, 2026
Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts
April 14, 2026
Tempest Therapeutics Announces Up To $6 Million Private Placement
March 23, 2026
Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026
March 11, 2026
←
Previous Page
1
2